PL1718338T3 - Kompozycje oraz sposoby do celowanego dostarczania leku in vitro oraz in vivo do ssaczych komórek poprzez bakteriopochodne nienaruszone minikomórki - Google Patents

Kompozycje oraz sposoby do celowanego dostarczania leku in vitro oraz in vivo do ssaczych komórek poprzez bakteriopochodne nienaruszone minikomórki

Info

Publication number
PL1718338T3
PL1718338T3 PL05702361T PL05702361T PL1718338T3 PL 1718338 T3 PL1718338 T3 PL 1718338T3 PL 05702361 T PL05702361 T PL 05702361T PL 05702361 T PL05702361 T PL 05702361T PL 1718338 T3 PL1718338 T3 PL 1718338T3
Authority
PL
Poland
Prior art keywords
vitro
targeted
compositions
methods
drug delivery
Prior art date
Application number
PL05702361T
Other languages
English (en)
Inventor
Himanshu Brahmbhatt
Jennifer Macdiarmid
Original Assignee
Engeneic Molecular Delivery Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engeneic Molecular Delivery Pty Ltd filed Critical Engeneic Molecular Delivery Pty Ltd
Publication of PL1718338T3 publication Critical patent/PL1718338T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL05702361T 2004-02-02 2005-01-27 Kompozycje oraz sposoby do celowanego dostarczania leku in vitro oraz in vivo do ssaczych komórek poprzez bakteriopochodne nienaruszone minikomórki PL1718338T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54059004P 2004-02-02 2004-02-02
EP20050702361 EP1718338B1 (en) 2004-02-02 2005-01-27 Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
PCT/IB2005/000204 WO2005079854A1 (en) 2004-02-02 2005-01-27 Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells

Publications (1)

Publication Number Publication Date
PL1718338T3 true PL1718338T3 (pl) 2015-12-31

Family

ID=34885947

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05702361T PL1718338T3 (pl) 2004-02-02 2005-01-27 Kompozycje oraz sposoby do celowanego dostarczania leku in vitro oraz in vivo do ssaczych komórek poprzez bakteriopochodne nienaruszone minikomórki

Country Status (18)

Country Link
US (3) US9867785B2 (pl)
EP (2) EP1718338B1 (pl)
JP (2) JP5060787B2 (pl)
CN (2) CN102028953B (pl)
AU (2) AU2005215254B2 (pl)
CA (2) CA2556248C (pl)
DK (2) DK1718338T3 (pl)
ES (2) ES2544652T3 (pl)
HR (1) HRP20150828T8 (pl)
HU (1) HUE025292T2 (pl)
ME (1) ME02251B (pl)
NZ (1) NZ549139A (pl)
PL (1) PL1718338T3 (pl)
PT (1) PT1718338E (pl)
RS (1) RS54149B1 (pl)
SG (3) SG135174A1 (pl)
SI (1) SI1718338T1 (pl)
WO (1) WO2005079854A1 (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004249172A1 (en) 2003-06-24 2004-12-29 Baxter International Inc. Specific delivery of drugs to the brain
US8986736B2 (en) 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
PL1718338T3 (pl) * 2004-02-02 2015-12-31 Engeneic Molecular Delivery Pty Ltd Kompozycje oraz sposoby do celowanego dostarczania leku in vitro oraz in vivo do ssaczych komórek poprzez bakteriopochodne nienaruszone minikomórki
RU2006144851A (ru) 2004-06-15 2008-06-20 Бакстер Интернэшнл Инк. (Us) Применение терапевтических средств ex-vivo в виде твердых микрочастиц
CN101072876B (zh) 2004-08-26 2012-11-28 恩杰内克分子递送有限公司 通过细菌性来源的完整小细胞向哺乳动物细胞递送功能性核酸
DK2865755T3 (en) 2007-03-30 2017-05-15 Engeneic Molecular Delivery Pty Ltd BACTERIAL DERIVATIVE INTACT MINICELLS WITH REGULATORY RNA
US8282930B2 (en) 2007-09-24 2012-10-09 The University Of Queensland Molecular delivery vehicle
KR20190085187A (ko) 2008-01-22 2019-07-17 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
CN101965195A (zh) 2008-03-05 2011-02-02 巴克斯特国际公司 用于药物投送的组合物和方法
KR101813824B1 (ko) 2008-06-25 2017-12-29 벡션 테라퓨틱스 엘엘씨 조절된 유전자 자살 메커니즘 조성물 및 방법
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
KR101314868B1 (ko) 2009-07-01 2013-10-08 주식회사이언메딕스 포유류의 유핵세포에서 유래된 마이크로베시클 및 이의 용도
IT1401457B1 (it) * 2010-06-11 2013-07-26 Fond I R C C S Istituto Neurologico Carlo Besta Carrier di tipo cellulare per il trasporto mirato di almeno una molecola e/o almeno un composto molecolare ad almeno una cellula bersaglio in un mammifero umano o non umano
US9149542B2 (en) 2010-07-01 2015-10-06 Aeon Medix Inc. Microvesicles derived from cell protoplast and use thereof
AU2012217728B2 (en) 2011-02-15 2017-04-27 Vaxiion Therapeutics, Llc Therapeutic compositions and methods for antibody and Fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells
SG11201403062YA (en) * 2011-12-13 2014-07-30 Engeneic Molecular Delivery Pty Ltd Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
EP3750562A1 (en) 2012-10-02 2020-12-16 Vaxiion Therapeutics, LLC Immunomodulatory minicells and methods of use
GB2521071A (en) * 2012-10-03 2015-06-10 Waters Technologies Corp Rapid analysis of steroids and steroid derivatives
CA2900454A1 (en) * 2013-02-07 2014-08-14 Glaxosmithkline Biologicals Sa Pharmaceutical compositions comprising vesicles
US10314916B2 (en) 2013-06-11 2019-06-11 House Wellness Foods Corporation Carrier for delivery of substance to phagocytes
TWI737576B (zh) 2013-10-04 2021-09-01 澳大利亞商安珍尼Ｉｃ分子輸送私人有限公司 使用藥物裝載之雙特異性配位體標靶的微型細胞與干擾素-γ的組合式腫瘤治療
CN106999444B (zh) * 2014-10-03 2023-12-12 安吉尼科分子传输公司 完整的细菌衍生的囊泡对小分子化合物的增强装载
CN104388459B (zh) * 2014-10-29 2017-03-08 四川农业大学 使细菌自主产微细胞的方法及一株自产微细胞细菌突变株
KR101708424B1 (ko) 2015-03-04 2017-02-20 전남대학교산학협력단 코리네박테리움 속 박테리아 및 이로부터 유래된 미니셀 그리고 이의 용도
JP6824960B2 (ja) 2015-08-04 2021-02-03 バキシオン セラピューティクス，リミテッド ライアビリティ カンパニー 細菌由来ミニ細胞型バイオ医薬品の電離放射線照射滅菌およびその使用方法
KR101858840B1 (ko) * 2016-01-15 2018-05-16 단국대학교 천안캠퍼스 산학협력단 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제
US10940112B2 (en) 2016-05-04 2021-03-09 L.E.A.F. Holdings Group Llc Targeted liposomal gemcitabine compositions and methods thereof
CA3039010A1 (en) 2016-10-06 2018-04-12 Engeneic Molecular Delivery Pty Ltd Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same
EP3649242A2 (en) 2017-07-06 2020-05-13 National University of Singapore Methods of inhibiting cell proliferation and mettl8 activity
WO2019204154A1 (en) 2018-04-18 2019-10-24 Reyoung Corporation Compositions and methods for treating liver cancer
WO2019217164A1 (en) 2018-05-09 2019-11-14 Reyoung Corporation Compositions and methods for treating cancer and other diseases
WO2020021437A1 (en) 2018-07-23 2020-01-30 Engeneic Molecular Delivery Pty Ltd Compositions comprising bacterially derived minicells and methods of using the same
SG11202105822WA (en) * 2018-12-10 2021-06-29 Flagship Pioneering Innovations Vi Llc Achromosomal dynamic active systems
JP7548911B2 (ja) 2019-01-04 2024-09-10 エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド 腫瘍性疾患の治療のためのカプセル化グリコリピド抗原
EP3952645A4 (en) * 2019-04-08 2023-08-23 University Of Massachusetts Localization of payload delivery systems to tumor sites via beacon cell targeting
US20220202950A1 (en) * 2019-05-01 2022-06-30 Engeneic Molecular Delivery Pty Ltd Compositions comprising bacterially derived intact minicells for theranostic applications
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CN114053430A (zh) * 2020-07-29 2022-02-18 深圳先进技术研究院 一种负载纳米载药颗粒的细菌及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4496778A (en) 1983-10-03 1985-01-29 Exxon Research & Engineering Co. Process for the hydroxylation of olefins using molecular oxygen, an osmium containing catalyst, a copper Co-catalyst, and an aromatic amine based promoter
CA1270198A (en) 1984-08-08 1990-06-12 Marcel B. Bally Encapsulation of antineoplastic agents in liposomes
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) * 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
DE69632859T2 (de) 1995-04-18 2005-07-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Verfahren zur Arzneistoffbehandlung von Liposomen Zusammensetzung
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
WO2000063364A2 (en) 1999-04-21 2000-10-26 American Home Products Corporation Methods and compositions for inhibiting the function of polynucleotide sequences
US6635448B2 (en) 2000-08-21 2003-10-21 Clonexdevelopment, Inc. Methods and compositions for increasing protein yield from a cell culture
IL157794A0 (en) 2001-03-07 2004-03-28 Childrens Medical Center Method to screen peptide display libraries using minicell display
US7011946B2 (en) 2001-05-22 2006-03-14 Trustees Of Tufts College In vivo assay for identification of antimicrobial agents
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
US20030166099A1 (en) * 2001-06-05 2003-09-04 Sabbadini Roger A. Minicells comprising membrane proteins
ATE541940T1 (de) * 2001-10-15 2012-02-15 Engeneic Molecular Delivery Pty Ltd Intakte minizellen als vektoren für dna-transfer und gentherapie in vitro und in vivo
AU2002318168B2 (en) * 2002-02-25 2007-12-13 Vaxiion Therapeutics, Llc Minicell compositions and methods
US20030203481A1 (en) * 2002-02-25 2003-10-30 Surber Mark W. Conjugated minicells
US20030207833A1 (en) 2002-02-25 2003-11-06 Neil Berkley Pharmaceutical compositions with minicells
US7611885B2 (en) 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
NZ547983A (en) 2003-12-09 2009-05-31 Engeneic Molecular Delivery Pty Ltd Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells
PL1718338T3 (pl) 2004-02-02 2015-12-31 Engeneic Molecular Delivery Pty Ltd Kompozycje oraz sposoby do celowanego dostarczania leku in vitro oraz in vivo do ssaczych komórek poprzez bakteriopochodne nienaruszone minikomórki
CN101072876B (zh) 2004-08-26 2012-11-28 恩杰内克分子递送有限公司 通过细菌性来源的完整小细胞向哺乳动物细胞递送功能性核酸
EP2270136A1 (en) 2004-12-17 2011-01-05 Beth Israel Deaconess Medical Center Compositions for bacterial mediated gene silencing and methods of using same
CN101505768B (zh) 2006-06-23 2013-11-06 因詹尼克分子递送控股有限公司 通过完整的死亡细菌细胞将药物、治疗性核酸和功能性核酸靶向递送至哺乳动物细胞

Also Published As

Publication number Publication date
AU2010200599A1 (en) 2010-03-11
NZ549139A (en) 2009-11-27
EP1718338A1 (en) 2006-11-08
JP5060787B2 (ja) 2012-10-31
CN1925873A (zh) 2007-03-07
EP2992901B1 (en) 2019-10-23
ES2765426T3 (es) 2020-06-09
SI1718338T1 (sl) 2015-09-30
CA2788707C (en) 2014-02-25
JP2011178798A (ja) 2011-09-15
EP1718338B1 (en) 2015-05-06
HUE025292T2 (en) 2016-02-29
WO2005079854A1 (en) 2005-09-01
DK1718338T3 (en) 2015-08-10
DK2992901T3 (da) 2020-01-27
HRP20150828T8 (hr) 2016-04-22
AU2005215254A1 (en) 2005-09-01
EP2992901A1 (en) 2016-03-09
CA2788707A1 (en) 2005-09-01
SG135175A1 (en) 2007-09-28
EP1718338A4 (en) 2009-07-22
SG135174A1 (en) 2007-09-28
RS54149B1 (sr) 2015-12-31
JP2007534667A (ja) 2007-11-29
US10799461B2 (en) 2020-10-13
US20180133163A1 (en) 2018-05-17
US20140220116A1 (en) 2014-08-07
ES2544652T3 (es) 2015-09-02
JP5571031B2 (ja) 2014-08-13
CN102028953A (zh) 2011-04-27
HK1155665A1 (en) 2012-05-25
AU2005215254B2 (en) 2009-11-12
CA2556248A1 (en) 2005-09-01
PT1718338E (pt) 2015-09-21
SG169373A1 (en) 2011-03-30
CN102028953B (zh) 2013-10-30
CN1925873B (zh) 2011-02-09
ME02251B (me) 2015-12-31
US20180280311A1 (en) 2018-10-04
HRP20150828T1 (xx) 2015-09-11
CA2556248C (en) 2013-04-02
US9867785B2 (en) 2018-01-16
AU2010200599B2 (en) 2011-09-22

Similar Documents

Publication Publication Date Title
SI1718338T1 (sl) Sestavki in metode za ciljno usmerjeno in vitro in in vivo dostavo zdravila v celice sesalcev preko bakterijsko pridobljenih intaktnih minicelic
EP1594883A4 (en) COVALENT MODIFICATION OF RNA FOR DISTRIBUTION IN VITRO / I AND IN VIVO / I
EP1791959A4 (en) DISPOSAL OF FUNCTIONAL NUCLEIC ACIDS ON MAMMALIAN CELLS OVER BACTERIA ORIGINAL INTACT MINIMIZERS
PL2089511T3 (pl) Rozrost in vitro komórek pochodzących z tkanki pępowinowej wykorzystujących mikronośniki
EP2049130A4 (en) SOFT TISSUE LOAD COMPOSITION COMPRISING AUTOLOGOUS CELL CULTURE PRODUCT DERIVED FROM DERMA AND HYALURONIC ACID
EP1636385A4 (en) INHIBITION OF GENE FUNCTION BY IN VIVO DISTRIBUTION OF GENE EXPRESSION INHIBITORS BASED ON POLYNUCLEOTIDES IN MAMMALIAN CELLS
WO2010062911A3 (en) Compositions and methods of functionally enhanced in vitro cell culture system
IL243462A (en) Oligomers and phosphate-based conjugates for insertion of drugs into living cells and cell nuclei
EP1585560A4 (en) ADMINISTRATION OF MOLECULES AND COMPLEXES TO IN VIVO MAMMAL CELLS
WO2007147014A8 (en) Method and systems for using biopolymer-based beads and hydrogels
IL186535A0 (en) Pharmaceutical compositions for elimination of heterogeneous and mixed cell populations in tumors
WO2011082038A3 (en) Improved reprogramming compositions
IL202184A (en) A method for enhancing the expression of exogenous T cell sequences, a method based kit, a pharmacological preparation containing at least one stimulatory substance and an adeno viral vector containing the exogenous sequence
WO2008147816A3 (en) Compositions and methods for the display of proteins on the surface of bacteria and their derived vesicles and uses thereof
EP2155235A4 (en) OXYGENIC COMPOSITIONS FOR IMPROVING THE SURVIVAL OF CELLS AND TISSUE IN VIVO
EP1589999A4 (en) POLYVINYL ETHER FOR THE ADMINISTRATION OF POLYNUCLEOTIDES IN MAMMALIAN CELLS
EP2506857A4 (en) ISSUE OF MRNA FOR THE PROTEIN AND ENZYME REPRODUCTION OF HUMAN-ENVIRONMENTAL DISEASES
WO2003099225A3 (en) Compositions for delivering nucleic acids to cells
EP4241767A3 (en) Novel lipids and compositions for the delivery of therapeutics
MX357691B (es) Il-15 y il-15r-alfa mejoradas para expresion en celulas mamiferas.
MX2012000455A (es) Composiciones de matriz extra-celular y medio acondicionado a partir de celulas cultivadas bajo condiciones hipoxicas.
FR2931163B1 (fr) Lignee de cellules dendritiques plasmacytoides utilisee en therapie cellulaire active ou adoptive
EP2488210A4 (en) METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION USING IN VITO OR IN VITRO-ADMINISTERED OLIGONUCLEOTIDE MEDICAMENTS
IL180077A (en) In vitro Methods, Their Use, and Preparations to Encourage Oligodendrocyte Differentiation or Survival Using Lingo-1 Antagonist Antibodies
WO2010056808A3 (en) Compositions and methods for re-programming and re-differentiating cells